SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01494402

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects

The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA following repeated administration in healthy male Japanese subjects.

NCT01494402 Bioequivalence Study

3 Interventions

Name: D961S

Description: Oral gelatine capsule

Type: Drug

D961S

Name: Esomeprazole

Description: Oral HPMC capsule

Type: Drug

esomeprazole + buffered acetylsalicylic acid

Name: Buffered acetylsalicylic acid

Description: Tablet

Type: Drug

esomeprazole + buffered acetylsalicylic acid


Primary Outcomes

Description: All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.

Measure: Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in terms of Area under the plasma concentration(AUCτ).

Time: Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6

Description: All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.

Measure: Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in term maximum plasma concentration (Cmax,ss)

Time: Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6

Secondary Outcomes

Description: All PK variables and plasma concentrations of esomeprazole, ASA and SA at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.

Measure: Description of D961S PK profile comparing to esomeprazole and ASA combination in terms of AUC0-t,ss, mean residence time (MRT), time to reach Cmax (tmax,ss) and t1/2,ss of esomeprazole and ASA, and AUCτ, Cmax,ss, AUC0-t,ss, MRT, tmax,ss and t1/2,ss of SA

Time: Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6

Description: Descriptive statistics will be provided for all safety variables, and the analyses will be performed according to the actual treatment. No formal comparison will be performed.

Measure: Description of Safety and tolerability profile of esomeprazole in combination with ASA in terms of adverse events, clinical laboratory tests, blood pressure, pulse rate and body temperature.

Time: Pre-entry, Day 5 of treatment period and follow up (5-7 days after last dose)

Purpose: Basic Science

Allocation: Randomized

Crossover Assignment


There is one SNP

SNPs


1 D961S

A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects. --- D961S ---

Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA following repeated administration in healthy male Japanese subjects. --- D961S ---

Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA following repeated administration in healthy male Japanese subjects. --- D961S --- --- D961S ---

Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA following repeated administration in healthy male Japanese subjects. --- D961S --- --- D961S --- --- D961S ---

Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in terms of Area under the plasma concentration(AUCτ).. --- D961S ---

All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.. Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in term maximum plasma concentration (Cmax,ss). --- D961S ---

All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.. Description of D961S PK profile comparing to esomeprazole and ASA combination in terms of AUC0-t,ss, mean residence time (MRT), time to reach Cmax (tmax,ss) and t1/2,ss of esomeprazole and ASA, and AUCτ, Cmax,ss, AUC0-t,ss, MRT, tmax,ss and t1/2,ss of SA. --- D961S ---

No formal comparison will be performed.. Inclusion Criteria: - Healthy Japanese males 20-45 years of age - Classified as homo-EM - Negative for HIV, Hepatitis B, Hepatitis C and syphilis - Body Mass Index (BMI=weight/height2) 19-27 (kg/m2) - Body weight 50-85 kg Exclusion Criteria: - Significant clinical illness from 2 weeks preceding the pre-entry visit to the randomization - Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease - Need for concomitant medication in the study - Past or present NSAIDs induced asthma - History of bleeding diathesis Inclusion Criteria: - Healthy Japanese males 20-45 years of age - Classified as homo-EM - Negative for HIV, Hepatitis B, Hepatitis C and syphilis - Body Mass Index (BMI=weight/height2) 19-27 (kg/m2) - Body weight 50-85 kg Exclusion Criteria: - Significant clinical illness from 2 weeks preceding the pre-entry visit to the randomization - Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease - Need for concomitant medication in the study - Past or present NSAIDs induced asthma - History of bleeding diathesis Bioequivalence Study A Phase I, Open label, Randomized, Single center, 2 way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) with a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects --- D961S ---



HPO Nodes